FindTrial
Sign In

How Pertuzumab Treatment Works for HER2-Positive Breast Cancer in day to day practice

Retrospective Assessment of Pertuzumab Therapy in Real-World Settings for the Management of HER2-Positive Breast Cancer: Clinical Characteristics and Treatment Outcomes. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/11/076798
Enrollment
125
Registered
2024-11-14
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: NA: NA Control Intervention1: NA: NA

Sponsors

Tata Memorial Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Histologically confirmed breast cancer displaying HER2-positive non-metastatic and metastatic breast cancer. 2 All her2-positive breast cancer patients who received pertuzumab and trastuzumab, irrespective of the duration of therapy and line of therapy.

Exclusion criteria

Exclusion criteria: 1 Patients with a history of HER2-positive breast cancer were not treated with Pertuzumab and Trastuzumab. 2 Participants with an unknown status regarding HER2. 3 Who are not treated in TMH or ACTREC.

Design outcomes

Primary

MeasureTime frame
Overall Survival (OS): To measure the overall survival.Timepoint: 2 Years—

Secondary

MeasureTime frame
-Progression-free survival -Response assessment by recist criteria -To assess toxicities developed as per CTCAE version 5.0 -Treatment Patterns AnalysisTimepoint: 2 years—

Countries

India

Contacts

Public ContactAnbarasan Sekar

Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre

anbarasan157@gmail.com8124227205

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026